866-997-4948(US-Canada Toll Free)

Iressa (Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022

Published By :

GlobalData

Published Date : Jun 2013

Category :

Cancer

No. of Pages : 56 Pages


Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer in men and women. Historically, the treatment paradigm has centered around chemotherapy. However, the launch of targeted therapies for patients with specific biomarkers has begun to fragment the NSCLC treatment landscape into smaller niche patient populations. Over the forecast period, this trend will continue with the launch of multiple new drugs in several new drug classes to address the high unmet need among NSCLC patients, and provide new treatment options for previously underserved populations. Launch of premium-priced drug candidates combined with increasing incident cases of the disease will be major drivers of growth in the major markets.

AstraZenecas once-daily oral EGFR TKI, Iressa is indicated for first-line use as a monotherapy for advanced-stage, EGFR-positive patients. It is approved for reimbursement for conditional first-line treatment in the UK (NICE, 2010). However, due to its failure to provide superior OS compared with standard chemotherapy in all patients, regardless of EGFR mutation, Iressas marketing status was revoked in the US by the FDA in 2005 (Iressa package insert, 2013). Iressa is marketed by AstraZeneca in the EU and Japan.

Scope

  • Overview of NSCLC, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Iressa including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Iressa for the top nine countries from 2012 to 2022.
  • Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, India and China.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for NSCLC
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Iressa performance
  • Obtain sales forecast for Iressa from 2012-2022 in top nine countries (the US, France, Germany, Italy, Spain, the UK, Japan, India and China)
Table of Contents

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7

2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 9
2.3 Upcoming Related Reports 11

3 Disease Overview 12
3.1 Etiology and Pathophysiology 12
3.1.1 Etiology 12
3.1.2 Pathophysiology and Histology 12
3.1.3 NSCLC Biomarkers 13
3.1.4 Quality of Life 14
3.2 Symptoms 15

4 Disease Management 17
4.1 Treatment Overview 17
4.1.1 Diagnosis 19
4.1.2 Clinical Staging 19
4.1.3 Screening and Early Detection 22
4.1.4 Localized Procedures and Therapies 23
4.1.5 Systemic Chemotherapy 24
4.1.6 Targeted Therapy 25

5 Competitive Assessment 28
5.1 Overview 28
5.2 Strategic Competitor Assessment 29

6 Iressa (gefitinib) 32
6.1 Overview 32
6.2 Efficacy 34
6.3 Safety 36
6.4 SWOT Analysis 36
6.5 Forecast 37

7 Appendix 38
7.1 Bibliography 38
7.2 Abbreviations 43
7.3 Methodology 46
7.4 Forecasting Methodology 46
7.4.1 Number of NSCLC Patients Currently Seeking Treatment 46
7.4.2 Percent Drug-treated Patients 47
7.4.3 General Pricing Assumptions 47
7.4.4 Individual Drug Assumptions 50
7.4.5 Generic Erosion 50
7.5 Physicians and Specialists Included in This Study 51
7.6 Survey of Prescribing Physicians 52
7.7 About the Authors 53
7.7.1 Author 53
7.7.2 Epidemiologist 53
7.7.3 Global Head of Healthcare 54
7.8 About GlobalData 55
7.9 Disclaimer 55

List of Table


Table 1: Symptoms of Disease NSCLC 16
Table 2: Treatment Guidelines for NSCLC 18
Table 3: Stage Definitions for NSCLC 21
Table 4: Treatment Overview by Stage of Diagnosis for NSCLC 27
Table 5: Leading Treatments for NSCLC 31
Table 6: Product Profile Iressa (gefitinib) 34
Table 7: Iressa SWOT Analysis, 2013 36
Table 8: Global Sales Forecasts ($m) for Iressa, 2012-2022 37
Table 9: Five Year Prevalence 47
Table 10: Physicians Surveyed by Country 52

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *